Accepted Manuscript

In Vitro Efficacy of Approved and Experimental Antivirals Against Novel Genotype 3 Hepatitis C Virus Subgenomic Replicons

Mei Yu, Amoreena C. Corsa, Simin Xu, Betty Peng, Ruoyu Gong, Yu-Jen Lee, Katie Chan, Hongmei Mo, William Delaney IV, Guofeng Cheng


PII: S0166-3542(13)00238-6

DOI: http://dx.doi.org/10.1016/j.antiviral.2013.08.018

Reference: AVR 3275

To appear in: Antiviral Research

Received Date: 17 December 2012 Revised Date: 22 August 2013 Accepted Date: 25 August 2013



Please cite this article as: Yu, M., Corsa, A.C., Xu, S., Peng, B., Gong, R., Lee, Y-J., Chan, K., Mo, H., Delaney, W. IV, Cheng, G., In Vitro Efficacy of Approved and Experimental Antivirals Against Novel Genotype 3 Hepatitis C Virus Subgenomic Replicons, *Antiviral Research* (2013), doi: http://dx.doi.org/10.1016/j.antiviral.2013.08.018

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

In Vitro Efficacy of Approved and Experimental Antivirals Against Novel Genotype 3 Hepatitis C Virus Subgenomic Replicons

Short Title – Development of Genotype 3a HCV Replicons and Evaluation of Antivirals

Mei Yu, Amoreena C. Corsa, Simin Xu, Betty Peng, Ruoyu Gong, Yu-Jen Lee, Katie Chan, Hongmei Mo, William Delaney IV, Guofeng Cheng

Biology Department, Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404

Grant Support – none

Abbreviations - HCV: hepatic C virus; GT: genotype; NS: non-structural; DAA: direct-acting antivirals; 2-CMeA: 2-C-methyl adenosine; CsA: cyclosporin A; Rluc: Renilla luciferase; RLU: relative light units; neo: neomycin transferase gene; G418: geneticin; EC₅₀: 50% effective inhibitory concentration

Correspondence - Guofeng Cheng, Gilead Science, 333 Lakeside Dr. Foster City, CA 94404. <u>Guofeng.cheng@gilead.com</u> Tel: 650 522-4236 Fax: 650 522-5890

Disclosures- All authors on this manuscript are stockholders and employees of Gilead Sciences. This manuscript contains information describing the in vitro activity of Gilead compounds currently in development as treatments for HCV.

Author Contributions - MY was involved in study design, data acquisition, and manuscript preparation; AC and BP were involved in study design; SX, RG, YL, KC and HM were involved in acquisition and analysis of data; WD and GC were involved in study concept, analysis and interpretation of data, study supervision and manuscript preparation.

Download English Version:

https://daneshyari.com/en/article/5822341

Download Persian Version:

https://daneshyari.com/article/5822341

<u>Daneshyari.com</u>